What this study adds
nerve injuries, cord injury

KCL‐286 was tested in healthy male adults to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of this agent under investigation for the treatment of spinal cord injury.Safety and pharmacokinetic data indicate that KCL‐286 is well tolerated at a 100‐mg daily dose, which equates to a dose shown to elicit axonal regeneration in proof‐of‐concept models of spinal cord injury.KCL‐286 engages its receptor in white blood cells and maintains activation during dosing.KCL‐286, as far as we are aware, is the first orally available RARβ agonist drug for treatment of nerve injuries.